Question 1

What is the catalog number for CHK1-IN-9?

Accepted Answer

The catalog number for CHK1-IN-9 is orb3133925.

Question 2

What sizes are available for CHK1-IN-9?

Accepted Answer

CHK1-IN-9 is available in the following size(s): 10 mg, 50 mg.

Question 3

How many pack sizes does CHK1-IN-9 come in?

Accepted Answer

CHK1-IN-9 is available in 2 different pack sizes.

Question 4

Is CHK1-IN-9 in stock?

Accepted Answer

CHK1-IN-9 is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is CHK1-IN-9 used for?

Accepted Answer

CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 of 0.55 nM. It enhances the effects of DNA-damaging agents on tumor cells and exhibits synergistic anticancer activity with Gemcitabine.

Question 6

What is the isotype of this antibody?

Accepted Answer

Isotype information such as IgG1 or IgG2a is listed in the product specifications on the datasheet, relevant for selecting compatible detection reagents.

Question 7

Can I get a trial-size or discounted first order of this product?

Accepted Answer

We don’t generally offer free samples, but trial discounts in exchange for feedback and validation results are almost always possible. Contact us with your intended application to arrange one.

Question 8

Do you offer bulk or custom quantities of this product?

Accepted Answer

Yes. Ordering two or more units, or combining this with other products, usually qualifies for a discount depending on quantity. Contact our sales team with your required volume for a custom quote.

CHK1-IN-9

Product Specifications

Field of Research

Storage Conditions

Notes

Available Sizes

Frequently Asked Questions

Explore Other Products

T Cell Receptor (TCR) alpha/beta Hamster Monoclonal Antibody [Clone ID: H57-597]

Ube2c Mouse Gene Knockout Kit (CRISPR)

FA12 (heavy chain, Cleaved-Ile20) Antibody

GLYAT (NM_005838) Human Over-expression Lysate

Giardia lamblia (BB1.1E5), CF488A conjugate, 0.1mg/mL

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, 0.1mg/mL